KUS187
KUS187 is an orally active VCP ATPase modulator that inhibits VCP ATPase activity and reduces cellular ATP consumption. KUS187 prevents MPP+, low Glucose (D-Glucose) (HY-B0389)-, and Tunicamycin (HY-A0098)-induced cytoplasmic and mitochondrial ATP depletion. KUS187 inhibits ER stress, suppresses AMPK activation, prevents loss of mitochondrial membrane potential and changes in mitophagy, and protects neurons from MPP+-induced death/neurite retraction. KUS187 can be used for research on Parkinson's disease, retinitis pigmentosa, and retinal ganglion cell injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1357164-95-4
- Formule: C27H25N4NaO5S
- Masse moléculaire:540.57
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform AMPK
More
Activité biologique
Description
In Vitro
KUS187 (50 μM; 24 h) preserves mitochondrial morphology, neurite mitochondrial length, and mitochondrial membrane potential in PC12 cells exposed to MPP+, but does not increase mitochondrial mass or reduce ROS[1].
KUS187 (25 μM; 24 h) protects primary midbrain dopaminergic neurons from MPP+-induced death and neurite atrophy[1].
KUS187 (30-1000 nM; 20 min) inhibits recombinant human VCP ATPase activity with an IC50 of 186 nM[2].
KUS187 (100 nM-1 mM; 20 min) decreased total soluble ATPase activity in lysates of neuronally differentiated PC12 cells, by approximately 20% at 100 nM and approximately 40% at 1 mM[2].
KUS187 (20 μM; 41 h) protects HeLa cells from Glucose-induced cell death[2].
KUS187 (20 μM; 41 h) protects HeLa cells from Tunicamycin-induced cell death[2].
KUS187 (50 μM; 5 h) prevents Tunicamycin-induced laminin c1 aggregation in HeLa cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Neuronally differentiated PC12 cells
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Preserved mitochondrial morphology, neurite mitochondrial length, and mitochondrial membrane potential in PC12 cells exposed to MPP+.
-
Cell Line:HeLa cells
-
Concentration:20 μM
-
Incubation Time:41 h
-
Result:Prevented low-Glucose-induced HeLa cell death.
-
Cell Line:HeLa cells
-
Concentration:20 μM
-
Incubation Time:41 h
-
Result:Protected HeLa cells from Tunicamycin-induced cell death.
-
Cell Line:HeLa cells
-
Concentration:50 μM
-
Incubation Time:5 h
-
Result:Suppressed Tunicamycin-induced CHOP and Grp78 expression and restored Akt phosphorylation at Ser473.
-
Cell Line:HeLa cells
-
Concentration:50 μM
-
Incubation Time:5 h
-
Result:Prevented Tunicamycin-induced aggregation of laminin c1.
Remained in a diffuse ER pattern.
In Vivo
KUS187 (50 mg/kg/day; oral; once daily; 7 days) alters retinal endothelin-related gene expression in C57/BL6 wild-type and B6.Cg-Tg (Ty1-CFP) 23Jrs/J mice with NMDA (HY-17551)-induced acute retinal ganglion cell injury, and shows lower EDN1/EDNRB immunostaining in the RGC layer relative to NMDA-injected controls[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 rd10 (PDE6B mutant; age P7-P33)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily; starting 7 days after birth
-
Result:Detected ONL and inner segment/outer segment junction line at P25 in KUS187-administered rd10 mice.
Showed almost normal electroretinography response in most KUS187-administered rd10 mice at P25.
Preserved thin ONL and electroretinography response at P29 in KUS187-administered rd10 mice.
Showed 5-6 ONL rows, observable photoreceptor outer segments, and small b-wave and oscillatory potentials at P33 in KUS187-administered rd10 mice.
Delayed disease progression based on time-dependent total retinal thickness and dark-adapted b-wave amplitudes.
Showed regularly arranged photoreceptor outer segments at P21 in KUS187-administered rd10 retinas.
Suppressed retinal CHOP expression at P21 in KUS187-administered rd10 mice.
-
Animal Model:C57/BL6 wild-type and B6.Cg-Tg(Ty1-CFP)23Jrs/J (male; 2-3 months old; NMDA-induced acute retinal ganglion cell damage)[3]
-
Dosage:50 mg/kg/day
-
Administration:p.o. (feeding tube); once daily; 7 days
-
Result:Showed higher Edn1 mRNA expression in neural retina in NMDA-injected KUS187-treated mice (n=8) than in non-treated wild-type mice (n=7).
Showed higher Ednrb mRNA expression in NMDA-injected control mice than in non-treated wild-type mice, whereas Ednrb mRNA expression in NMDA-injected KUS187-treated mice did not differ from non-treated wild-type mice.
Showed no difference in Ednra mRNA expression among groups.
Downregulated 136 transcripts (95 genes) <0.5-fold by KUS187 administration relative to NMDA-saline among 387 transcripts upregulated >2-fold by NMDA-saline.
Upregulated 93 transcripts (74 genes) >2-fold by KUS187 administration relative to NMDA-saline among 335 transcripts downregulated <0.5-fold by NMDA-saline.
Showed lower EDN1 and EDNRB protein expression in the RGC layer in NMDA-injected KUS187-treated mice (n=2) than in NMDA-injected control mice (n=3) by immunostaining of retinal sections.
Chemical Information
-
CAS No. 1357164-95-4
-
Masse moléculaire 540.57
-
Formule C27H25N4NaO5S
-
SMILES
O=CC1=CC(C)=CC(C2=NC=C(C=C2)/N=N/C3=C(N)C4=C(C=CC=C4)C(S(=O)(O[Na])=O)=C3)=C1OCCCC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KUS187 Related Classifications
HY-134499 Related Classifications
Powered by Bioz